NASDAQ:BJDX Bluejay Diagnostics (BJDX) Stock Price, News & Analysis $1.45 +0.04 (+2.84%) Closing price 04:00 PM EasternExtended Trading$1.43 -0.02 (-1.38%) As of 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Bluejay Diagnostics Stock (NASDAQ:BJDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bluejay Diagnostics alerts:Sign Up Key Stats Today's Range$1.37▼$1.4750-Day Range$1.30▼$1.8852-Week Range$1.26▼$12.45Volume83,444 shsAverage Volume1.34 million shsMarket Capitalization$2.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts. Read More Bluejay Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks6th Percentile Overall ScoreBJDX MarketRank™: Bluejay Diagnostics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Bluejay Diagnostics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Bluejay Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bluejay Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBluejay Diagnostics has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.02% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 262.05%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBluejay Diagnostics does not currently pay a dividend.Dividend GrowthBluejay Diagnostics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.02% of the float of Bluejay Diagnostics has been sold short.Short Interest Ratio / Days to CoverBluejay Diagnostics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bluejay Diagnostics has recently increased by 262.05%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment-0.01 News SentimentBluejay Diagnostics has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bluejay Diagnostics this week, compared to 0 articles on an average week.Search Interest4 people have searched for BJDX on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat Follows2 people have added Bluejay Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Bluejay Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.08% of the stock of Bluejay Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 18.47% of the stock of Bluejay Diagnostics is held by institutions.Read more about Bluejay Diagnostics' insider trading history. Receive BJDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bluejay Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BJDX Stock News HeadlinesShort Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Increases By 262.0%September 4 at 3:37 AM | americanbankingnews.comBluejay Diagnostics Announces Board Leadership ChangesAugust 16, 2025 | msn.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.September 5 at 2:00 AM | Porter & Company (Ad)Bluejay Diagnostics, Inc.: Bluejay Diagnostics Provides Second Quarter Business and Corporate UpdateAugust 8, 2025 | finanznachrichten.deBluejay Diagnostics Provides Second Quarter Business and Corporate UpdateAugust 7, 2025 | globenewswire.comBluejay Diagnostics Amends Agreement with Toray IndustriesJuly 29, 2025 | msn.comBJDX - Bluejay Diagnostics Inc Ownership - MorningstarJuly 2, 2025 | morningstar.comMBluejay Diagnostics advances sepsis test, plans FDA filingJune 5, 2025 | investing.comSee More Headlines BJDX Stock Analysis - Frequently Asked Questions How have BJDX shares performed this year? Bluejay Diagnostics' stock was trading at $4.87 at the beginning of 2025. Since then, BJDX shares have decreased by 70.2% and is now trading at $1.45. How were Bluejay Diagnostics' earnings last quarter? Bluejay Diagnostics, Inc. (NASDAQ:BJDX) released its quarterly earnings data on Thursday, August, 7th. The company reported ($1.41) earnings per share (EPS) for the quarter. When did Bluejay Diagnostics' stock split? Bluejay Diagnostics's stock reverse split before market open on Thursday, June 20th 2024.The 1-8 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Bluejay Diagnostics IPO? Bluejay Diagnostics (BJDX) raised $22 million in an initial public offering (IPO) on Wednesday, November 10th 2021. The company issued 2,160,000 shares at a price of $10.00 per share. How do I buy shares of Bluejay Diagnostics? Shares of BJDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bluejay Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bluejay Diagnostics investors own include SoFi Technologies (SOFI), Athenex (ATNX), V.F. (VFC), Allarity Therapeutics (ALLR), Andersons (ANDE) and British American Tobacco (BTI). Company Calendar Last Earnings8/07/2025Today9/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolNASDAQ:BJDX CIK1704287 Webwww.bluejaydx.com Phone844-327-7078FaxN/AEmployees9Year FoundedN/AProfitability EPS (Trailing Twelve Months)($125.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-362.07% Return on Assets-299.10% Debt Debt-to-Equity RatioN/A Current Ratio4.56 Quick Ratio4.56 Sales & Book Value Annual Sales$250 thousand Price / Sales8.46 Cash FlowN/A Price / Cash FlowN/A Book Value$10.34 per share Price / Book0.14Miscellaneous Outstanding Shares1,490,000Free Float1,493,000Market Cap$2.12 million OptionableNot Optionable Beta0.48 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:BJDX) was last updated on 9/5/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.